Japanese drugmaker Daiichi Sankyo (4568.T) said on Tuesday it would buy privately held pharmaceutical firm Plexxikon Inc of the United States for about $805 million dollars, aiming to grow its oncology business. Daiichi is aiming to take advantage of a late-stage cancer drug, PLX4032, which California-based Plexxikon is jointly developing with Roche (ROG.VX). The Japanese firm will pay up to an additional $130 million dollars based on the drug's successful launch, Daiichi said in a statement.
Source
